1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Clene Inc.

Clene Inc.

CLNNW
Clene Inc.US flagNASDAQ Capital Market
0.00
USD
+0.00
- -
2.16MMarket Cap
Clene Inc.
CLNNW
(NASDAQ Capital Market)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
1
- -
1
- -
- -
- -
Sales/Revenue/Turnover
- -
-7,337.38
-6,262.24
-9,420.08
-5,850.15
-9,349.42
-10,908
-14,878.36
Operating Margin (%)
1
1
1
1
2
2
1
1
Depreciation Expense
-16
-19
-10
-30
-50
-39
-26
-34
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-9,357.77
-1,347.16
-6,325.16
-7,569.42
-11,520.47
-13,086.5
-25,009.7
Profit Margin (%)
5
51
49
15
14
6
-2
6
Working Capital
2
4
24
25
12
20
17
19
LT Debt
-68
- -
13
3
13
-9
-18
-19
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2
5
3
LT Borrowings
16
14
16
LT Finance Leases
3
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
11
12
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
13
9
13
Cash, Cash Equivalents & STI
8
5
6
Accounts Receivable, Net
- -
- -
3
Inventories
- -
- -
- -
Total Current Liabilities
8
11
7
Payables & Accruals
2
1
2
ST Debt
2
5
3
Deferred Revenue
1
2
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
753.19%
98.62%
Free Cash Flow
- -
7.03%
-12.91%
Net Income, GAAP
- -
33.84%
-33.57%
Sales/Revenue/Turnover
- -
33.09%
-41.52%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Xenetic Biosciences, Inc. (XBIOW)
Ambrx Biopharma Inc. (AMAM)
Checkmate Pharmaceuticals, Inc. (CMPI)
ProKidney Corp. (PROK)
AnGes, Inc. (AMGXF)
Solegreen Ltd (SLGN.TA)
Business
Clene Inc. is a late clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics aimed at treating neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson's disease. The company's core product pipeline includes CNM-Au8, an oral suspension of gold nanocrystals designed to restore neuronal health and function by enhancing cellular energy production and reducing oxidative stress; CNM-ZnAg, a broad-spectrum antiviral agent composed of silver and zinc nanocrystals targeting infectious diseases and wound healing; and CNM-AgZn17, a gel polymer suspension of zinc and silver ions also aimed at infectious disease treatment. Clene operates through its wholly owned subsidiary Clene Nanomedicine Inc., leveraging its electro-crystal-chemistry drug platform to produce stable nanocrystal suspensions for therapeutic use. Founded in 2020 and headquartered in Salt Lake City, Utah, Clene serves a global biopharmaceutical market focused on high unmet medical needs in neurodegenerative and infectious diseases. Recent major developments include the completion of FDA-recommended biomarker analyses for CNM-Au8 in ALS patients, demonstrating statistically significant reductions in disease biomarkers supporting potential disease-modifying effects. Clene plans to submit a New Drug Application (NDA) for CNM-Au8 under the FDA's accelerated approval pathway in the first quarter of 2026, with a Phase 3 RESTORE-ALS trial planned as the post-approval confirmatory study. The company hosted an investor call in December 2025 to update on the CNM-Au8 program and continues to invest in expanding its nanotherapeutics pipeline designed to improve mitochondrial health and protect neuronal function. Clene's technology platform and clinical-stage assets position it as an innovative player in the biotechnology sector with a focused strategy on addressing neurodegenerative and infectious diseases worldwide.